Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents

To reduce 5-fluorouracil (5-FU)-induced serious toxicities without loss of antitumor activity, we have developed DFP-11207, a novel fluoropyrimidine, which consists of 1-ethoxymethyl-5-fluorouracil (EM-FU; a precursor form of 5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP; an inhibitor of 5-FU degradat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukushima, Masakazu, Iizuka, Kenzo, Jin, Cheng, Zhang, Chun, Hong, Mei, Eshima, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472421/
https://www.ncbi.nlm.nih.gov/pubmed/28652707
http://dx.doi.org/10.2147/DDDT.S128420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472421/
https://www.ncbi.nlm.nih.gov/pubmed/28652707
http://dx.doi.org/10.2147/DDDT.S128420

Ejemplares similares